No Evidence of Long-Term Immunosuppression after High-Titer Edmonstron-Zagreb Measles Vaccination in Senegal

Samb, Badara; Whittle, Hilton; Aaby, Péter; Seck, Awa; Bennett, John E.; Markowitz, Lauri E.; Ngom, Pa Tamba; Zeller, H.; Michaelsen, Kim F.; Simondon, François

doi:10.1093/infdis/171.2.506

Cited by 16 publications

(7 citation statements)

References 5 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar decrease in CD4 1 /CD8 1 T-cell ratios was observed in girls in Guinea-Bissau 3 to 5 years after vaccination with high-titer measles vaccine (62). However, these findings were not confirmed in Senegal (80) and the increased risk of mortality did not extend to more than 36 months after vaccination in any study.…”

Section: Unintended Immunologic Consequences Of Measles Vaccinationsupporting

confidence: 54%

Immune Responses to Measles and Measles Vaccine: Challenges for Measles Control

Moss

Polack

2001

Viral Immunology

View full text Add to dashboard Cite

Most strategies for reducing global measles morbidity and mortality and eliminating measles are based on the ability to enhance immune responses to measles virus. Challenges to measles elimination and eradication are based in part on the need to sustain high levels of population immunity to interrupt transmission of measles virus. We review aspects of the immunology of measles and measles vaccination with the aim of demonstrating how knowledge of the immune responses is essential to furthering the goals of reducing measles morbidity and mortality and the elimination of measles. Better understanding of the mechanisms of immune suppression after measles, the potential for alternative vaccination strategies to induce immunity in young infants, and the immunologic basis of atypical measles, increased mortality after high-titer measles vaccine, and waning immunity will lead to improved strategies for measles control and elimination.

show abstract

Section: Unintended Immunologic Consequences Of Measles Vaccinationsupporting

confidence: 54%

Immune Responses to Measles and Measles Vaccine: Challenges for Measles Control

Moss

Polack

2001

Viral Immunology

View full text Add to dashboard Cite

show abstract

“…Three studies have investigated the effect of co‐administration of MCV with other vaccines. One study showed that female infants, who are vaccinated with high‐dose Edmonstron‐Zagreb measles vaccine at the same time as receiving a rabies vaccine, have higher antibodies against rabies 3 months after vaccination compared to female infants who do not receive the vaccine . Another study showed that when MMR is given simultaneously with a yellow fever vaccine, antibody concentrations and seroprotection rates to yellow fever are lower than when the vaccines are given more than a month apart .…”

Section: Discussionmentioning

confidence: 99%

“…The antibody response to heterologous vaccines provides one way to explore these effects. Only three studies have investigated the influence of MCV on heterologous vaccine responses and these reported inconsistent results . In these studies, a MCV was given at the same time as the other vaccines.…”

Section: Introductionmentioning

confidence: 99%

“…Only three studies have investigated the influence of MCV on heterologous vaccine responses and these reported inconsistent results. [13][14][15] In these studies, a MCV was given at the same time as the other vaccines. We hypothesized that through effects on innate immunity, stimulation of B-and T-lymphocytes and expansion of pre-existing memory cells, a MCV might alter heterologous responses to previously administered vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The immunomodulatory effects of measles‐mumps‐rubella vaccination on persistence of heterologous vaccine responses

et al. 2019

View full text Add to dashboard Cite

It is proposed that measles‐containing vaccines have immunomodulatory effects which include a reduction in all‐cause childhood mortality. The antibody response to heterologous vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles‐mumps‐rubella (MMR) vaccine on the persistence of antibodies to a broad range of heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b‐meningococcus C (Hib‐MenC) vaccines while the remaining 99 children had not yet received these vaccines. In the MMR/Hib‐MenC‐vaccinated group, blood was taken 28 ± 14 days after receiving these vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC‐Hib‐vaccinated and MMR/MenC‐Hib‐naïve participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib‐MenC‐vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib‐MenC‐vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to heterologous vaccines received in the first year of life.

show abstract

“…Accordingly, time of vaccination has been linked to differences in T cell populations and strength and type of heterologous immune response (73,74). Sex-specific differences in terms of protective non-specific effects of vaccines such as measles and vaccinia (64,(75)(76)(77)(78)(79)(80) have also been described. Modification of vaccine composition (e.g., enrichment of particular proteins or epitopes) or conditions of administration (e.g., age, dose, number of immunizations) could potentially help us achieve the beneficial heterologous effects of vaccines without compromising their primary protective effects (vaccine specific).…”

Section: Implications For Vaccine Developmentmentioning

confidence: 99%